The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated d
- PDF / 3,185,961 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 11 Downloads / 162 Views
ORIGINAL PAPER
The association of body mass index with long‑term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub‑analysis of the GLOBAL LEADERS Trial Masafumi Ono1 · Ply Chichareon1,2 · Mariusz Tomaniak3,4 · Hideyuki Kawashima1 · Kuniaki Takahashi1 · Norihiro Kogame1 · Rodrigo Modolo1,5 · Hironori Hara1 · Chao Gao6,7 · Rutao Wang6,7 · Simon Walsh8 · Harry Suryapranata6 · Pedro Canas da Silva9 · James Cotton10 · René Koning11 · Ibrahim Akin12 · Benno J. W. M. Rensing13 · Scot Garg14 · Joanna J. Wykrzykowska1 · Jan J. Piek1 · Peter Jüni15 · Christian Hamm16 · Philippe Gabriel Steg17 · Marco Valgimigli18 · Stephan Windecker18 · Robert F. Storey19 · Yoshinobu Onuma20 · Pascal Vranckx21 · Patrick W. Serruys20,22 Received: 3 December 2019 / Accepted: 16 January 2020 © The Author(s) 2020
Abstract Background The efficacy of antiplatelet therapies following percutaneous coronary intervention (PCI) may be affected by body mass index (BMI). Methods and results This is a prespecified subgroup analysis of the GLOBAL LEADERS trial, a prospective, multicenter, open-label, randomized controlled trial in an all-comer population undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with a reference regimen (12-month aspirin monotherapy following 12-month DAPT). A total of 15,968 patients were stratified by baseline BMI with prespecified threshold of 27 kg/m2. Of those, 6973 (43.7%) patients with a BMI
Data Loading...
